Epitomics, Inc.

Apexigen, Inc.

Jiangsu Simcere Pharmaceutical R&d Co., Ltd

Jiangsu Simcere Pharmaceutical Co., Ltd

Yaohuang Ke

Weimin Zhu

Guo-Liang Yu

Robert Pytela

Qi Qian

Harry C Au

Yongke Zhang

Sum Wai Pierre Lee

Karin Vroom

Pierre Li

Guoliang Yu

Fanxin Ma

Xin Fan

The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications.

Fusion partner for production of monoclonal rabbit antibodies

The present invention provides anti-IL-6R monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.

Anti-IL-6 receptor antibodies and methods of use

The present invention provides anti-KDR monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of a variety of cancers, rheumatoid arthritis, diabetic retinopathy and other diseases associated with aberrant VEGF or KDR expression and/or activity.

Anti-KDR antibodies and methods of use

An antibody that binds TNF &#x3b1; and neutralizes its activity is provided. In certain cases, the antibody comprises: a) a heavy chain variable domain comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO. 1, and b) a light chain variable domain comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID No. 2.

Anti-TNF&#x3b1; antibody

The present invention provides anti-IL-1&#x3b2; monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of inflammatory and other diseases.

Anti-IL-1&#x3b2; antibodies

A method of obtaining nucleic acid encoding a plurality of antibodies is provided. In certain embodiments, the method comprises obtaining from an immunized animal nucleic acid encoding the amino acid sequence of the heavy and light chains of a second antibody that binds to the antigen as a first antibody and differs in amino acid sequence to the first antibody, wherein the obtaining is done by amplification using: i. a first primer pair that includes oligonucleotides are complementary to CDR-encoding regions first antibody.

CDR-anchored amplification method

In certain embodiments, the method may comprises: a) contacting a population of permeabilized, cross-linked antibody-producing cells with a labeled antigen to produce a labeled sample in which cells that produce an antibody that specifically binds to said antigen are intracellularly labeled; b) using FACS to isolate cells that are intracellularly labeled, thereby producing labeled cells; c) uncrosslinking said labeled cells to produce uncrosslinked cells; and d) amplifying heavy and light chain-encoding nucleic acid from individual uncrosslinked cells, thereby obtaining nucleic acid that encodes the variable domain of antibody that specifically binds to said antigen.

FACS-based method for obtaining an antibody sequence

The present invention provides an anti-VEGF monoclonal antibody, which has the variable region of heavy chain comprising the amino acid sequences of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, and/or the variable region of light chain comprising the amino acid sequences of SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6. The antibody can be produced by the cell line with the preservation number of CGMCC NO. 3233. The invention also provides the use of said antibody for the manufacture of medicaments for the treatment of a disease that is relevant to VEGF, wherein further provided are pharmaceutical composition, agents, kits and chips comprising said antibody, as well as the cell line with the preservation number of CGMCC NO. 3233.

Anti-VEGF monoclonal antibody and pharmaceutical composition comprising said antibody

An antibody is provided. In certain cases, the antibody comprises: a) a heavy chain variable domain that comprises CDR regions that are substantially identical to the heavy chain CDR regions of a selected antibody and b) a light chain variable domain that comprises CDR regions that are substantially identical to the light chain CDR regions of the selected antibody, where the antibody binds a selected target.

Growing community of inventors

San Francisco, CA, United States of America

Yaohuang Ke